2020
FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
So-Armah KA, Lim JK, Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team V. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress In Cardiovascular Diseases 2020, 63: 184-191. PMID: 32068085, PMCID: PMC7278895, DOI: 10.1016/j.pcad.2020.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHealth StatusHeart FailureHepatitis CHIV InfectionsHIV Long-Term SurvivorsHumansIncidenceLiver CirrhosisMaleMiddle AgedPrognosisRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsUnited StatesVentricular Function, LeftVeterans HealthViral LoadConceptsType of HFIncident heart failureHeart failureHepatitis C statusAdvanced fibrosisLiver fibrosisEjection fractionHazard ratioC statusVeterans Aging Cohort StudyRisk of HFpEFLast clinic visitReduced ejection fractionAging Cohort StudyLiver fibrosis scoresPrevalent cardiovascular diseaseFirst HF eventProportional hazards modelIncident HFpEFHepatitis CClinic visitsCohort studyPrimary outcomeFibrosis scoreHF eventsPrevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature
Muiruri C, Longenecker CT, Meissner EG, Okeke NL, Pettit AC, Thomas K, Velazquez E, Bloomfield GS. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. Progress In Cardiovascular Diseases 2020, 63: 142-148. PMID: 32057785, PMCID: PMC7237291, DOI: 10.1016/j.pcad.2020.02.006.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCardiovascular DiseasesComorbidityHealth Status DisparitiesHealthcare DisparitiesHIV InfectionsHIV Long-Term SurvivorsHumansPreventive Health ServicesPrognosisProtective FactorsRace FactorsRisk AssessmentRisk FactorsSocial Determinants of HealthSocial MarginalizationSocioeconomic FactorsViral LoadVulnerable PopulationsConceptsHuman immunodeficiency virusCardiovascular diseaseComorbid human immunodeficiency virusNarrative reviewSocial determinantsRacial disparitiesCommon social determinantsEthnic disparities persistEthnic groupsCVD morbidityImmunodeficiency virusClinical practiceTranslation of researchClinical researchDisparities persistDiseaseHealthDisparitiesGroupMorbidityReviewPersonsPreventionReceipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV
Shahrir S, Crothers K, McGinnis KA, Chan KCG, Baeten JM, Wilson SM, Butt AA, Pisani MA, Baldassarri SR, Justice A, Williams EC. Receipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV. Progress In Cardiovascular Diseases 2020, 63: 118-124. PMID: 31987807, PMCID: PMC7251937, DOI: 10.1016/j.pcad.2020.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsCardiovascular DiseasesFemaleHealth StatusHIV InfectionsHIV Long-Term SurvivorsHumansLongitudinal StudiesMaleMiddle AgedPreventive Health ServicesProspective StudiesProtective FactorsRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokersSmokingSmoking CessationSmoking Cessation AgentsTime FactorsTreatment OutcomeUnited StatesVeterans HealthViral LoadConceptsNicotine replacement therapyVeterans Aging Cohort StudyMultivariable log-linear regression modelsPotential treatment disparitiesSmoking cessation pharmacotherapyPatient-level factorsAging Cohort StudyMental health disordersRates of receiptUninfected participantsUninfected patientsCardiovascular riskCessation pharmacotherapyCohort studyCurrent smokingHIV statusMultivariable analysisTreatment disparitiesReplacement therapyRelative riskHealth disordersPharmacotherapyPLWHSmokingHIV
2019
Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members
Gonzalo-Gil E, Rapuano PB, Ikediobi U, Leibowitz R, Mehta S, Coskun AK, Porterfield JZ, Lampkin TD, Marconi VC, Rimland D, Walker BD, Deeks S, Sutton RE. Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members. ELife 2019, 8: e44360. PMID: 30964004, PMCID: PMC6456299, DOI: 10.7554/elife.44360.Peer-Reviewed Original ResearchConceptsAccessible chromatinActive transcriptionATAC-seqNearby genesCell surface expressionChromosome 3p21Genetic determinantsFamily membersT cell activationHost genetic determinantsResistance phenotypeChemokine receptor mRNACCR5 cell surface expressionRNA levelsCell activationPhenotypeT cellsCellsChromatinTranscriptionGenesKbMembersReceptor mRNAMRNA
2015
Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers
Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. Journal Of Virology 2015, 89: 5502-5514. PMID: 25740989, PMCID: PMC4442529, DOI: 10.1128/jvi.00118-15.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesCD4-Positive T-LymphocytesChemokine CCL3Chemokine CCL4Chemokine CCL5Chemokines, CCCohort StudiesFemaleGene DosageHIV InfectionsHIV Long-Term SurvivorsHIV-1Host-Pathogen InteractionsHumansMacrophage Inflammatory ProteinsMaleMiddle AgedReceptors, CCR5Receptors, CXCR4RNA, MessengerUp-RegulationConceptsElite controllersHIV-seropositive individualsAntiretroviral therapyT cellsMIP-1βMIP-1αHIV infectionSeropositive individualsAbsence of ARTR5-tropic HIV-1Macrophage inflammatory protein-1αR5-tropic HIVInflammatory protein-1αT cell resistancePandemic health problemRANTES chemokinesHIV replicationRare patientsHealthy controlsTherapeutic effectHIV entryHIV-1X4-tropicHealth problemsProtein-1α
2014
Chronic Diseases in HIV Survivors
Vermund SH, Narayan KM, Glass RI. Chronic Diseases in HIV Survivors. Science Translational Medicine 2014, 6: 241ed14-241ed14. PMID: 24944191, DOI: 10.1126/scitranslmed.3008684.Peer-Reviewed Original Research
2013
Evolution of an Attenuated HIV-1 Isolate in an Elite Suppressor
Salgado M, Gandhi S, Buckheit R, Berkenblit G, Blankson J. Evolution of an Attenuated HIV-1 Isolate in an Elite Suppressor. AIDS Research And Human Retroviruses 2013, 30: 284-288. PMID: 24117037, PMCID: PMC3938915, DOI: 10.1089/aid.2013.0229.Peer-Reviewed Original Research
2010
Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers
Justice A, McGinnis K, Skanderson M, Chang C, Gibert C, Goetz M, Rimland D, Rodriguez‐Barradas M, Oursler K, Brown, Braithwaite R, May M, Covinsky K, Roberts, Fultz S, Bryant K, Team F. Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers. HIV Medicine 2010, 11: 143-151. PMID: 19751364, PMCID: PMC3077949, DOI: 10.1111/j.1468-1293.2009.00757.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsBiomarkersCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionDrug Therapy, CombinationFemaleHepatitis, Viral, HumanHIV InfectionsHIV Long-Term SurvivorsHumansLiver CirrhosisMaleMiddle AgedRNA, ViralSeverity of Illness IndexSubstance-Related DisordersSurvival AnalysisConceptsCombination antiretroviral therapyVeterans Aging Cohort StudyHIV biomarkersVACS IndexHIV infectionSurvival intervalAging Cohort StudyShorter survival intervalAntiretroviral therapyCause mortalityCohort studyHIV markersPrognostic indexAIDS conditionsChronic inflammationMortality riskHIVSubstance abuseBiomarkersMortalityBiomarker groupsComplete dataSimilar intervalsInfectionFurther validation
2006
Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors
Blankson J, Bailey J, Thayil S, Yang H, Lassen K, Lai J, Gandhi S, Siliciano J, Williams T, Siliciano R. Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors. Journal Of Virology 2006, 81: 2508-2518. PMID: 17151109, PMCID: PMC1865922, DOI: 10.1128/jvi.02165-06.Peer-Reviewed Original ResearchConceptsReplication-competent HIV-1Human immunodeficiency virus type 1Immunodeficiency virus type 1Elite suppressorsVirus type 1HIV-1Replication-Competent Human Immunodeficiency Virus Type 1Untreated human immunodeficiency virus type 1Type 1Active antiretroviral therapyUndetectable viral loadReplication-competent virusAntiretroviral therapyImmunologic controlViral loadCoculture assaysPatientsDefective virusCurrent assaysFull-length sequencingVirusIsolatesAssaysPhenotypic analysisViremia
1999
Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. Evaluating supervised haart in late-stage HIV among drug users: A preliminary report. Journal Of Urban Health 1999, 76: 468-480. PMID: 10609596, PMCID: PMC3456696, DOI: 10.1007/bf02351504.Peer-Reviewed Original ResearchConceptsInjection drug usersResidential health care facilitiesViral load increaseViral loadDrug usersMean age 42 yearsHepatitis C virus antibodyHuman immunodeficiency virus (HIV) infectionActive antiretroviral therapyC virus antibodyTreatment-experienced patientsImmunodeficiency virus infectionAge 42 yearsHistory of dementiaLate-stage HIVHealth care facilitiesHIV/AIDSHCV seropositivityAntiretroviral therapyInitial CD4IDU populationRecord reviewSupervised therapyVirus antibodiesMedication administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply